近日,先声药业宣布,其与安帝康生物合作开发的抗流感1类创新药玛氘诺沙韦新药上市申请获国家药品监督管理局受理,用于治疗成人及青少年无并发症的甲型和乙型流感。据《全国法定传染病疫情概况》数据显示,2023年11月,流感发病人数为1862998万;2024年11月,流感发病人数为166917人。玛氘诺沙韦片是一款抗流感新药,已经在3期临床中确证了对成人和青少年甲流、乙流治疗的有效性与安全性。值得一提的是...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.